ClinConnect ClinConnect Logo
Search / Trial NCT06976099

Multicenter Prospective Cohort Study of Hypertriglyceridemia Acute Pancreatitis

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · May 8, 2025

Trial Information

Current as of July 12, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Aged between 18 and 80 years;
  • Diagnosed with AP based on at least two of the following criteria (1) acute onset of upper abdominal pain; (2) more than three times the upper limit of the normal range of serum lipase or amylase levels; and (3) typical radiological findings of AP on computed tomography (CT), magnetic resonance imaging, or ultrasonography;
  • HTG with serum triglyceride levels \>500 mg/dL (5.65 mmol/L) during the current AP episode or at admission;
  • Patients must have good compliance, with the ability and willingness to adhere to study protocols, provide written informed consent, and maintain their current lifestyle during the study period
  • Exclusion Criteria:
  • History of chronic pancreatitis or pancreatic cancer;
  • Severe comorbidities such as malignancy, acute myocardial infarction, or extensive cerebral infarction;
  • Prior use of lipid-lowering medications;
  • Pregnancy or breastfeeding;
  • Lack of signed informed consent.

About Peking Union Medical College Hospital

Peking Union Medical College Hospital (PUMCH) is a prestigious medical institution and a leading research facility located in Beijing, China. Affiliated with the Chinese Academy of Medical Sciences, PUMCH is renowned for its commitment to advancing healthcare through innovative clinical research and high-quality patient care. The hospital plays a pivotal role in the development and execution of clinical trials across various medical disciplines, focusing on improving treatment outcomes and enhancing medical knowledge. With a multidisciplinary team of experts and state-of-the-art facilities, PUMCH is dedicated to contributing to global health advancements and fostering collaborations in the medical research community.

Locations

Beijing, Beijing, China

Guangzhou, Guangdong, China

Nanjing, Jiangsu, China

Dalian, Liaoning, China

Xi'an, Shaanxi, China

Harbin, Heilongjiang, China

Hangzhou, Zhejiang, China

Zunyi, Guizhou, China

Changsha, Hunan, China

Yangzhou, Jiangsu, China

Beijing, Beijing, China

Hangzhou, Zhejiang, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported